Literature DB >> 24501216

Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits.

Jonathan W Yau1, Peng Liao, James C Fredenburgh, Alan R Stafford, Alexey S Revenko, Brett P Monia, Jeffrey I Weitz.   

Abstract

Central venous catheter thrombosis can cause venous obstruction and pulmonary embolism. To determine the extent to which catheter thrombosis is triggered by the contact or extrinsic pathway of coagulation, we used antisense oligonucleotides (ASOs) to selectively knock down factor (f)XII, fXI, or high-molecular-weight kininogen (HK), key components of the contact pathway, or fVII, which is essential for the extrinsic pathway. Knockdown of contact pathway components prolonged the activated partial thromboplastin time and decreased target protein activity levels by over 90%, whereas fVII knockdown prolonged the prothrombin time and reduced fVII activity to a similar extent. Using a rabbit model of catheter thrombosis, catheters implanted in the jugular vein were assessed daily until they occluded, up to a maximum of 35 days. Compared with control, fXII and fXI ASO treatment prolonged the time to catheter occlusion by 2.2- and 2.3-fold, respectively. In contrast, both HK and fVII knockdown did not significantly prolong the time to occlusion, and dual treatment with fVII- and fXI-directed ASOs produced a time to occlusion similar to that with the fXI ASO alone. These findings suggest that catheter thrombosis is triggered via the contact pathway and identify fXII and fXI as potential targets to attenuate this complication.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24501216     DOI: 10.1182/blood-2013-12-540872

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

2.  Polyphosphate nanoparticles on the platelet surface trigger contact system activation.

Authors:  Johan J F Verhoef; Arjan D Barendrecht; Katrin F Nickel; Kim Dijkxhoorn; Ellinor Kenne; Linda Labberton; Owen J T McCarty; Raymond Schiffelers; Harry F Heijnen; Antoni P Hendrickx; Huub Schellekens; Marcel H Fens; Steven de Maat; Thomas Renné; Coen Maas
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

3.  The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.

Authors:  Katrin F Nickel; Göran Ronquist; Florian Langer; Linda Labberton; Tobias A Fuchs; Carsten Bokemeyer; Guido Sauter; Markus Graefen; Nigel Mackman; Evi X Stavrou; Gunnar Ronquist; Thomas Renné
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

Review 4.  Anticoagulation therapy in 2015: where we are and where we are going.

Authors:  Jeffrey I Weitz
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 5.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 6.  Anti-fouling strategies for central venous catheters.

Authors:  Alex Wallace; Hassan Albadawi; Nikasha Patel; Ali Khademhosseini; Yu Shrike Zhang; Sailendra Naidu; Grace Knuttinen; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

7.  FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow.

Authors:  Shu Zhu; Richard J Travers; James H Morrissey; Scott L Diamond
Journal:  Blood       Date:  2015-07-01       Impact factor: 22.113

Review 8.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 9.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

10.  A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Authors:  Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani
Journal:  Thromb Res       Date:  2016-02-18       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.